ReviewExpert opinion on drug delivery2009
Strategies for the targeted delivery of therapeutics for osteosarcoma.
Review in Expert opinion on drug delivery, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Chinese Herbal Medicine for Osteosarcoma in the Mouse: A Systematic Review and Meta-Analysis.Chinese journal of integrative medicine · 2019Pooled it
- MicroRNAs for osteosarcoma in the mouse: a meta-analysis.Oncotarget · 2016Pooled it
- Acetyl-CoA synthase 1 mediates metabolic reprogramming to promote proliferation and metastasis of osteosarcoma.Journal of orthopaedic translation · 2026Article
- Bone targeted nano-drug and nano-delivery.Bone research · 2024Review
- Clemastine and hyperthermia enhance sensitization of osteosarcoma cells for apoptosis.Molecular & cellular oncology · 2024Article
- Berberine and Cisplatin Exhibit Synergistic Anticancer Effects on Osteosarcoma MG-63 Cells by Inhibiting the MAPK Pathway.Molecules (Basel, Switzerland) · 2021Article
- LINC00174 Facilitates Cell Proliferation, Cell Migration and Tumor Growth of OsteosarcomaFrontiers in molecular biosciences · 2021Article
- Sterically stabilized recombined HDL composed of modified apolipoprotein A-I for efficient targeting toward glioma cells.Drug delivery · 2020Article
- Circular RNA Circ-03955 Promotes Epithelial-Mesenchymal Transition in Osteosarcoma by Regulating miR-3662/Metadherin Pathway.Frontiers in oncology · 2020Article
- Caffeine citrate enhanced cisplatin antitumor effects in osteosarcoma and fibrosarcoma in vitro and in vivo.BMC cancer · 2019Article
- Global analysis of osteosarcoma lipidomes reveal altered lipid profiles in metastatic versus nonmetastatic cells.Journal of lipid research · 2019Article
- Non-Viral Delivery System and Targeted Bone Disease Therapy.International journal of molecular sciences · 2019Review
- Glucose-Regulated Protein 94 Modulates the Response of Osteosarcoma to Chemotherapy.Disease markers · 2019Article
- Bisphosphonate conjugation for bone specific drug targeting.Bone reports · 2018Review
- Combination of electroporation delivered metabolic modulators with low-dose chemotherapy in osteosarcoma.Oncotarget · 2018Article
- MicroRNA-192 inhibits the proliferation, migration and invasion of osteosarcoma cells and promotes apoptosis by targeting matrix metalloproteinase-11.Oncology letters · 2018Article
- Metformin inhibits the proliferation and metastasis of osteosarcoma cells by suppressing the phosphorylation of Akt.Oncology letters · 2018Article
- Long non-coding RNAs for osteosarcoma in the mouse: a meta-analysis.Oncotarget · 2017Article
- Down regulation of human positive coactivator 4 suppress tumorigenesis and lung metastasis of osteosarcoma.Oncotarget · 2017Article
- Identification of candidate drugs for the treatment of metastatic osteosarcoma through a subpathway analysis method.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
backgroundConventional therapy for osteosarcoma has reached a plateau of 60 - 70%, a 5-year survival rate that has changed little in two decades, highlighting the need for new approaches.
objectiveTo review the alternative means of delivering effective therapy for osteosarcoma that reach beyond the central venous catheter.
methodsDrawing on the author's own experiences providing care to high-risk osteosarcoma patients and reviewing the last two decades of literature describing sarcoma therapy, available information is summarized about potential osteosarcoma treatments that deliver therapy by a less conventional route. RESULTS/
conclusionsIntra-arterial chemotherapy has a limited impact on survival, but may help to achieve a better limb salvage. Intrapleural chemotherapy is important for managing malignant effusions. The development of inhalation therapies, treatments that target new bone formation such as bisphosphonates, chemically targeted radiation and antibody-based therapies all have potential to improve osteosarcoma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.